Tesamorelin is a modified form of growth hormone-releasing hormone, often shortened to GHRH. Researchers study it as an upstream signal: a message to a receptor involved in the growth-hormone pathway, rather than growth hormone itself.
What researchers investigate
- GHRH signaling: Investigate how receptor activation changes downstream cellular responses.
- GH and IGF-1 pathways: Study the relationship between an upstream signal and the responses measured later in the pathway.
- Metabolic models: Explore how endocrine signals relate to metabolic measurements under controlled conditions.
What makes it different?
Tesamorelin acts through the GHRH pathway. It is not growth hormone and is different from ghrelin-receptor agonists such as ipamorelin.
Research findings describe the materials and conditions studied; they do not predict results in people.
























